Skip to main content
Fig. 3 | Biomarker Research

Fig. 3

From: Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies

Fig. 3

Mutation distribution of HER2 bypass signaling pathway, PI3K/Akt/mTOR pathway and TP53 in ctDNA of baseline samples and its association with survival outcome. A Mutation distribution of HER2 bypass signaling pathway, PI3K/Akt/mTOR pathway and TP53 in ctDNA of baseline samples. B Kaplan-Meier estimates of progression-free survival comparing patients harbored concomitant mutations from multiple pathways in above HER2-related signaling network to those with none or one genetic alteration. C Kaplan-Meier estimates of overall survival comparing patients harbored concomitant mutations from multiple pathways in above HER2-related signaling network to those with none or one genetic alteration

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us